undefined undefined
NaN.000
NaN.00%
Evercore ISI Group:维持89bio(ETNB.US)评级,由优于大市调整至优于大市评级, 目标价由37.00美元调整至33.00美元。
05-15 08:21
Oppenheimer analyst Jay Olson maintained a Hold rating on 89bio (ETNB – Researc...
05-14 19:56
美国知名金融服务公司Cantor Fitzgerald在最近发布的一份报告中挑选了14只生物科技股,并认为这些股票被严重低估,值得“重新审视”。
05-13 14:43
Cantor Fitzgerald has selected its 14 top picks for biotech stocks that it regards as significantly undervalued and worth a "fresh" look. All of the picks were down more than 20% year-to-date, as of M...
05-12 23:00
SAN FRANCISCO, April 17, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasd...
04-18 04:05
Madrigal Pharmaceuticals (NASDAQ:MDGL) said that its recently approved NASH/MASH drug Rezdiffra is now available in the US through a specialty pharmacy network. Rezdiffra, also known as resmetirom, re...
04-09 22:03
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts jus...
03-28 00:30
国际咨询公司Research Nester称,到2035年,全球非酒精性脂肪性肝炎(NASH)治疗市场预计将达到483亿美元。
03-18 09:00
·Rezdiffra是40年来首款获FDA批准上市的MASH药物。过去十年,MASH一直是药物研发热点,但由于发病机制复杂,进展寥寥。辉瑞、百时美施贵宝、吉利德...
03-18 08:34
Oppenheimer analyst Jay Olson maintains 89bio (NASDAQ:ETNB) from Perform to Perform.
03-05 20:48